8,888 Newborns Over One Year: Evaluation of a Universal Neonatal Hearing Screening Program
International Archives of Otorhinolaryngology · 01.10.2026 · 30 (04) · 001-010
DOI: 10.1055/a-2804-5197 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Archives of Otorhinolaryngology, erschienen am 01.10.2026. Verfasst von Laura Franco Chiriboga und 4 weiteren Autor:innen. Beteiligte Einrichtung: PhD in Health, Interdisciplinarity, and Rehabilitation Universal Neonatal Hearing Screening Program, Hospital Maternidade de Campinas, Campinas, São …. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Universal Newborn Hearing Screening is essential for early detection of hearing loss, enabling prompt interventions and improving child development. To analyze the outcomes of a universal neonatal hearing screening program. Retrospective descriptive study analyzing the results of neonatal hearing screening. The inclusion criterion was birth at or transfer to the hospital between January and December 2023. The research was approved by the Research Ethics Committee, under number 5.227.720/2022. 8,828 (99.32% of total sample) underwent screening, with 7,846 having no risk factors for hearing loss and 982 identified with risk factors for hearing loss. Among the 60 newborns who were not screened, 7 (0.08%) were transferred to other hospitals before undergoing the universal neonatal hearing screening, 50 (0.56%) passed away, and 3 (0.03%) were lost to follow-up and did not undergo the screening. For the TEOAE and aABR tests, the variables sex, type of healthcare service, and birth weight had a significant effect on increasing the likelihood of test failures. The outcomes of one year of the UNHS service were assessed, revealing a coverage rate of 99.96%. The service meets the quality indicators recommended by the guidelines, except for the percentage of referrals for diagnosis. Although challenges remain and new goals are yet to be achieved, the importance of conducting further research is recognized to monitor the auditory development of infants throughout life, especially those with risk factors for hearing loss.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- PhD in Health, Interdisciplinarity, and Rehabilitation Universal Neonatal Hearing Screening Program, Hospital Maternidade de Campinas, Campinas, São Paulo, Brazil.
- PhD in Child and Adolescent Health Universal Neonatal Hearing Screening Program, Hospital Maternidade de Campinas, Campinas, São Paulo, Brazil.
- PhD in Public Health Federal University of Espírito Santo - Vitória/Espírito Santo - Brazil.
- PhD in Communication Disorders Universal Neonatal Hearing Screening Program, Hospital Maternidade de Campinas, Campinas, São Paulo, Brazil.
- Doctor Otorhinolaryngologist, Universal Neonatal Hearing Screening Program, Hospital Maternidade de Campinas, Campinas, São Paulo, Brazil.
ORCID-Profile: Laura Franco Chiriboga, Karolina Pessote Sideri, Jonathan Grassi, Elaine Soares Monteiro Pinto, Luis Miguel Chiriboga Arteta
Zitieren
APA
Chiriboga, L. F., Sideri, K. P., Grassi, J., Pinto, E. S. M., & Arteta, L. M. C. (2026). 8,888 Newborns Over One Year: Evaluation of a Universal Neonatal Hearing Screening Program. International Archives of Otorhinolaryngology, 30(04), 001-010. https://doi.org/10.1055/a-2804-5197
Vancouver
Chiriboga LF, Sideri KP, Grassi J, Pinto ESM, Arteta LMC. 8,888 Newborns Over One Year: Evaluation of a Universal Neonatal Hearing Screening Program. International Archives of Otorhinolaryngology. 2026;30(04):001-010. doi:10.1055/a-2804-5197
BibTeX
@article{Chiriboga2026,
author = {Chiriboga, Laura Franco and Sideri, Karolina Pessote and Grassi, Jonathan and Pinto, Elaine Soares Monteiro and Arteta, Luis Miguel Chiriboga},
title = {8,888 Newborns Over One Year: Evaluation of a Universal Neonatal Hearing Screening Program},
journal = {International Archives of Otorhinolaryngology},
year = {2026},
volume = {30},
number = {04},
pages = {001--010},
doi = {10.1055/a-2804-5197}
}
EUVIMED